Alunbrig access in Kuwait: the MOH-KDFC named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical & regulatory team. This page combines the Kuwait country research module with the Alunbrig drug module to describe the path families actually walk.

Quick orientation

Alunbrig (brigatinib) is an oral, once-daily second-generation anaplastic lymphoma kinase (ALK) inhibitor developed approximately by Takeda Oncology, with US FDA approval in 2017 (accelerated) and full approval in 2020 for ALK-positive metastatic non-small cell lung cancer (NSCLC). It is one of the small set of ALK inhibitors used as first-line or post-crizotinib therapy and has clinical evidence supporting CNS activity for brain-metastatic ALK-positive disease. For a Kuwait family weighing this option, the practical question is rarely whether brigatinib is the right drug. It typically already is. The practical question is how to get it to the patient when KCCC, Sheikh Jaber Al-Ahmad Al-Sabah Hospital, or a private oncology service does not have the molecule on hand. Reserved for you.

Why Alunbrig is hard to source in Kuwait

ALK-positive NSCLC is a small fraction of all NSCLC cases, approximately 3 to 7 percent depending on the population studied, and within the Kuwait NSCLC population the eligible cohort is small in absolute numbers. Three structural realities follow from that. First, hospital pharmacy formularies frequently stock only one or two ALK inhibitors (often alectinib or lorlatinib) and the consultant's preferred sequencing choice may not be the stocked option. Second, Alunbrig may be registered through the GCC central pathway or in-country at any given review date, but registration does not equal stocking, and stocking does not equal continuous supply for a small-population indication. Third, manufacturer prioritisation of cross-border launches favours larger GCC markets first, so Kuwait launch timing for a new ALK inhibitor often lags Saudi Arabia and the United Arab Emirates by 12 to 24 months.

The clinical consequence is real. ALK-positive NSCLC patients on first-line therapy who progress need a defined next-line option in days to weeks, not months. The named-patient pathway exists to close exactly that gap for the individual patient whose consultant has decided brigatinib is the next move. Brain-metastatic ALK-positive NSCLC patients have a further reason for sequencing-specific drug selection, because the CNS penetration profile across the ALK inhibitor class is not uniform and the consultant's clinical judgment on the right CNS-active option for the individual patient is part of the case.

The Kuwait MOH-KDFC named-patient pathway applied to Alunbrig

The pathway for a Kuwait-licensed consultant to obtain an unregistered or unstocked medicine for a specific patient is the unregistered-medicine personal-import permit administered by the Kuwait Drug & Food Control Administration (KDFC) under the Ministry of Health. For Alunbrig, the standard application set applies. The clinical justification letter from the treating medical oncologist or thoracic oncologist documents the diagnosis (ALK-positive NSCLC confirmed by FISH, IHC, or next-generation sequencing), the disease stage, the prior therapy sequence and outcome (typically crizotinib or another first-line ALK inhibitor, the progression event, and any CNS imaging findings), and the rationale for brigatinib at this point in the sequencing tree.

A complete KDFC application for an Alunbrig case typically includes the clinical justification letter, the treating consultant's Kuwait Medical Council registration verification, an anonymised patient identifier (or Civil ID for nationals and residents), product details for brigatinib (Alunbrig, brigatinib, Takeda, 90 mg and 180 mg tablets, the planned starting dose with the 7-day 90 mg lead-in followed by 180 mg daily, and the requested treatment duration), the destination dispensing facility name with license number and pharmacy in charge, and the chain-of-custody plan from the US manufacturer through the Kuwait importer to the dispensing pharmacy. Routine KDFC submissions process in 7 to 21 business days. Urgent oncology submissions routed through KCCC can sometimes receive expedited review, although timelines remain at the authority's discretion and are not promised.

Real costs in KWD and USD

The US wholesale acquisition cost for a 30-day supply of Alunbrig at the 180 mg once-daily maintenance dose is approximately USD 21,000 per month for the drug itself. The lead-in 90 mg starting week is a fraction of that. At the indicative exchange of 1 KWD to 3.25 USD, the monthly drug cost translates to approximately KWD 6,450. The Kuwaiti dinar is the highest-valued currency unit in the world by exchange rate, so the cost looks smaller in KWD than in USD, but the underlying USD cost is what drives the manufacturer release price and shipping economics. Reserve Meds quotes always render both currencies on the firm quote.

Drug cost is not the entire cost. International logistics for an ambient-temperature oral oncology tablet to Kuwait International Airport, customs clearance, KDFC permit fee, and Reserve Meds' concierge fee are itemised separately. Total all-in for a one-month Alunbrig supply delivered to a Kuwait dispensing pharmacy typically lands in the USD 22,500 to 24,000 range (approximately KWD 6,900 to 7,400), with the drug itself dominating the line items. For multi-month supply windows, per-month logistics cost falls. Insurance in Kuwait handles named-patient oncology imports case by case. The MOH public-system specialty pharmacy routinely covers brigatinib for Kuwaiti nationals dispensed through KCCC or other public-system oncology services. For expatriate patients on Afya or private employer plans, pre-authorisation is the norm. We supply the documentation set that lets your insurer assess the case. We do not promise coverage from any insurer.

Timing: what to expect

The KDFC permit itself is not the long pole for most cases. Routine submissions process in 7 to 21 business days; urgent oncology submissions routed through KCCC sometimes process faster. The patient-experience timeline runs from the consultant's prescription decision through documentation assembly (Reserve Meds returns a documentation kit to the physician within 24 to 48 hours of waitlist intake), permit filing, US-side sourcing alignment, manufacturer release, air freight to Kuwait International Airport, customs clearance, and dispensing-pharmacy intake. A typical first-cycle window for ambient oral oncology tablets to Kuwait is 3 to 5 weeks from waitlist intake to first dose, dependent on consultant documentation turnaround and KDFC processing speed. Refill cycles, once the first import is established and the consultant intends to continue brigatinib past the first month, typically run faster because the documentation set is largely reusable.

One ALK-inhibitor-specific timing note. Brigatinib's labeled starting schedule is 90 mg once daily for 7 days followed by 180 mg once daily ongoing. The 7-day lead-in is part of the safety profile to identify early pulmonary events. Reserve Meds defaults to a 90-day initial pull to cover the lead-in week plus 12 weeks of maintenance with operating margin, then continues monthly or quarterly as the consultant directs. Continuity across refills matters more than any single shipment, because a stockout mid-cycle on a targeted oncology agent has clinical consequence.

What your physician needs

The clinical justification letter for an Alunbrig KDFC submission typically addresses the diagnosis (ALK-positive NSCLC with the ALK-rearrangement test method and result), the disease stage and any CNS involvement, the documented sequence of prior systemic therapy (most commonly crizotinib first-line with the progression event documented; less commonly post-alectinib or post-ceritinib), the rationale for brigatinib at this point (CNS activity profile for brain-metastatic disease, tolerability versus alternative options, sequencing strategy), the planned dosing (90 mg once daily for 7 days followed by 180 mg once daily ongoing, with dose-reduction plan documented), and the planned monitoring (interstitial lung disease and pneumonitis monitoring per the boxed warning, hypertension monitoring, creatine phosphokinase, lipase, pancreatic enzymes, and routine LFTs).

Two documents sit alongside the letter. The treating consultant's Kuwait Medical Council registration verification, which the consultant or hospital HR holds, is part of the submission. The patient and family informed consent for a Kuwait dispensing facility's named-patient import is documented before the KDFC submission goes in. For a Kuwait public-system case, the dispensing facility is typically KCCC or another MOH oncology service; for private cases, Dar Al Shifa, New Mowasat, Royale Hayat, or Taiba Hospital are common dispensing sites depending on the consultant's primary affiliation.

KCCC and the Kuwait specialty-dispensing network

Kuwait Cancer Control Center (KCCC) at the Sabah Health Region in Shuwaikh is the national referral center for medical oncology, hematologic oncology, radiation oncology, and bone marrow transplantation, and it dispenses the highest concentration of specialty oncology imports in Kuwait. KCCC routinely files KDFC named-patient permits for unregistered ALK inhibitors, BTK inhibitors, and other oral targeted oncology therapies. Sheikh Jaber Al-Ahmad Al-Sabah Hospital in Jaber Al-Ahmad City carries multispecialty oncology capacity at the largest hospital in Kuwait by bed count, opened in 2018. Mubarak Al-Kabeer Hospital in Jabriya, affiliated with the Kuwait University Faculty of Medicine, carries tertiary internal medicine and hematology capacity. Al-Sabah Hospital, on the same Sabah campus as KCCC, anchors the densest cluster of public specialty pharmacy infrastructure in the country.

On the private side, Dar Al Shifa Hospital in Hawalli is a long-established multispecialty hospital with oncology and hematology service lines. Royale Hayat Hospital in Jabriya, Taiba Hospital in Sabah Al-Salem, New Mowasat Hospital in Salmiya, and Al Salam International Hospital in Bneid Al-Gar each carry private oncology service lines that work with Kuwait-licensed specialty importers on named-patient cases. Reserve Meds does not select the dispensing facility on the patient's behalf. We work with the dispensing facility the consultant has named.

Pharmacovigilance and cold-chain

Alunbrig is an ambient-temperature oral tablet. It does not require cold-chain transit, although it must be protected from extremes of temperature during the Kuwait summer when ambient airport-to-hospital transit temperatures regularly exceed 45 degrees Celsius. Reserve Meds ships ambient oral oncology tablets in insulated outer cartons with the product in original manufacturer pack-out, with temperature data loggers on every shipment to document compliance with the labeled storage range.

Pharmacovigilance reporting for Alunbrig in Kuwait runs through the KDFC Drug Safety Department, working with the GCC Centre for Pharmacovigilance based in Riyadh. The treating consultant and the dispensing facility share a duty to report adverse drug reactions. Serious adverse reactions (interstitial lung disease and pneumonitis, severe hypertension, severe LFT elevations, pancreatitis, bradycardia, vision disorders, severe creatine phosphokinase elevation with rhabdomyolysis) typically require reporting within 15 calendar days. Reserve Meds does not file adverse-event reports on the consultant's behalf; the obligation sits with the prescriber and the dispensing facility.

Common questions about Alunbrig in Kuwait

Will the MOH public-system specialty pharmacy cover this for Kuwaiti nationals? The MOH public-system specialty pharmacy at KCCC routinely covers ALK inhibitors for Kuwaiti nationals when the consultant medical oncologist documents the case through the standard KDFC named-patient channel. Coverage is case-by-case for expatriate patients on Afya or private employer plans. We supply the documentation set that lets the payer assess the case. We do not promise coverage.

Will my Kuwait Medical Council-registered consultant's letter be sufficient? Yes. Any Kuwait-licensed medical oncologist or thoracic oncologist in active consultant standing has signing authority on the clinical justification letter. KCCC consultants file these submissions routinely. Private-hospital consultants typically route through their hospital pharmacy or a Kuwait-licensed specialty importer who holds a KDFC pharmaceutical establishment licence.

Is Alunbrig a controlled substance? No. Alunbrig is not a DEA-scheduled substance. The MOH Narcotic and Psychotropic Drugs Control framework does not apply. Standard KDFC named-patient permit documentation is sufficient.

What if my consultant prefers alectinib or lorlatinib instead? Reserve Meds does not steer the clinical decision. The choice among ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) rests with the treating oncology team and reflects sequencing strategy, CNS activity profile, tolerability considerations, and prior-therapy exposure. We source whichever ALK inhibitor the consultant has named.

What about the ALTA-1L sequencing case? The ALTA-1L trial established brigatinib as a first-line option versus crizotinib in ALK-positive NSCLC, and that case is part of the contemporary first-line sequencing discussion. The clinical justification letter typically references the consultant's specific sequencing rationale rather than the trial citation in isolation.

Where Reserve Meds fits in Alunbrig cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating oncologist, the KDFC, the dispensing pharmacy, or your Kuwait consultant. For an Alunbrig case specifically, our work is the documentation kit, the US-side sourcing of the manufacturer pack, the cold-chain or ambient shipment to Kuwait International Airport, the chain-of-custody handoff to your Kuwait importer or hospital pharmacy, and the named-coordinator continuity through refill cycles. We identify the relevant approved jurisdiction for the family's circumstances. We document the institutional capability questions the consultant should ask. We assemble the regulatory documentation kit. We hold one named coordinator through the case. ALK-positive NSCLC cases run on continuity. Reserve Meds is built for that continuity. Reserved for you.

Next step

If a treating oncologist in Kuwait is weighing Alunbrig for a patient, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the consultant.

Join the Alunbrig waitlist

Reserved for you.

Related

• Alunbrig clinical resource
• Alunbrig in Saudi Arabia
• Alunbrig in the UAE
• Kuwait country page

Sources

1. FDA approval, Alunbrig (brigatinib), Takeda Pharmaceutical Company; accelerated approval 2017, full approval 2020 for ALK-positive metastati